The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...

Eli Lilly focuses on genetic medicine, developing treatments for diabetes, heart disease, deafness, Parkinson's, and Alzheimer's. Expanding in India.

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Patients at risk for heart disease experienced significant reductions in apolipoprotein B and LDL cholesterol levels on ...

Eli Lilly rolled out positive Phase 2 results for lepodisiran, a therapy targeting lipoprotein(a)—that genetic party crasher ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

Eli Lilly (NYSE: LLY) is advancing its ambitions in cardiometabolic medicine with new mid-stage data showing that solbinsiran ...

Inherited or genetic heart disorders, mostly known as Hypertrophic cardiomyopathy (HCM) in medical term, is a condition affecting the left ventricle, the main p ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

A single dose of an experimental drug has been found to reduce the risk of genetic heart disease by at least 94 per cent. Lepodisiran, developed by Eli Lilly, has shown promising results in reducing ...

Lilly's lepodisiran shows a 94% reduction in heart disease risk by lowering lipoprotein(a) levels, offering a breakthrough in cardiovascular innovation.

New drug shows promise in lowering Lp(a), a hidden heart risk factor. Especially vital for Black Americans, who often have ...